EXELON ECONOMICS ANALYSIS

Embed Size (px)

Citation preview

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    1/14

    Exelon

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    2/14

    Research outline:

    Objective.

    Introduction.

    Market Value.

    Market share.

    Company portfolio.

    Our product. Factors affect Supply.

    Factors affect Demand.

    Supply.

    Demand.

    Supply and Demand. Elasticity.

    Conclusions.

    References.

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    3/14

    Objective

    To study Exelon as Anti-Alzheimer product its

    Supply, Demand, Elasticity and the factors

    affecting it.

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    4/14

    Introduction

    Anti-Alzheimer market in Egypt;

    Market type: Oligopoly market

    it has main 3 players from a 3 multinational

    companies taking the largest market share

    and their activities has a direct effect on the

    total market.

    We are going to study Exelon in this Market

    for the years 2008,2009,2010 and 2011

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    5/14

    Market Value

    0

    5000000

    10000000

    15000000

    20000000

    25000000

    30000000

    35000000

    40000000

    y08 y09 y10 y11

    Money

    Money

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    6/14

    Company Portfolio

    Novartis:

    Its a multinational pharmaceutical company in 2012ranked No.1 sales wise in Egypt .

    Headquartered in Basel, Novartis employs nearly

    96,000 people worldwide and has a presence in over140 countries.

    The company's pharmaceutical products cover a widerange of therapeutic areas such as: oncology, blood

    diseases, cardiovascular diseases, organtransplant,tissue, immunity, neuroscience, ophthalmology, highblood pressure, respiratory diseases, rheumatism andarthritis.

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    7/14

    Our Product (Exelon)

    Exelon (rivastigmine): Anti-Alzheimer

    Class: Cholinestrase inhibitor.

    Mechanism of action:

    prevents the breakdown of Acetylcholine(neurotransmitter in the brain) through theinhibition of both Acetylcholine estrase andbuterylcholine estrase.

    Indication: FDA approved for treatment of mild tomoderate Alzheimer dementia and Parkinsondementia.

    It has 2 forms: Exelon caps and patches

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    8/14

    Factors affecting Supply

    Input prices

    Technology

    Expectations Number of sellers

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    9/14

    Supply

    0

    100000

    200000

    300000

    400000

    500000

    600000

    700000

    800000

    900000

    1000000

    Supply

    Supply

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    10/14

    Factors affecting Demand

    Consumer income

    Prices of related goods

    Expectations

    Number of buyers

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    11/14

    Demand

    0

    100000

    200000

    300000

    400000

    500000

    600000

    700000

    800000

    900000

    1000000

    Demand

    Demand

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    12/14

    Supply and Demand

    0

    100000

    200000

    300000

    400000

    500000

    600000

    700000

    800000

    900000

    1000000

    Demand

    Supply

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    13/14

    Elasticity

    Price elasticity of demand=

    percent change in quantity demanded

    percent change in price

    Price elasticity of demand for Exelon is 0.77

    so its Inelastic Demand

  • 7/29/2019 EXELON ECONOMICS ANALYSIS

    14/14

    Price elasticity of Supply=

    percent change in quantity Supplied

    percent change in price

    Price elasticity of Supply for Exelon is 0.25

    so its Inelastic Supply